Low renal but high extrarenal phenotype variability in Schimke immuno-osseous dysplasia

• Verfasst von: Lipska-Ziętkiewicz, Beata S. [VerfasserIn]
• Verfasst von: Trautmann, Agnes [VerfasserIn]
• Verfasst von: Schaefer, Franz [VerfasserIn]
• Titel: Low renal but high extrarenal phenotype variability in Schimke immuno-osseous dysplasia
• Verf.angabe: Beata S. Lipska-Ziętkiewicz, Jutta Gellermann, Olivia Boyer, Olivier Gribouval, Szymon Ziętkiewicz, Jameela A. Kari, Mohamed A. Shalaby, Fatih Ozaltin, Jiri Dusek, Anette Melk, Aysun K. Bayazit, Laura Massella, Lidia Hyla-Klekot, Sandra Habbig, Astrid Godron, Maria Szczepańska, Beata Bieniaś, Dorota Drożdż, Rasha Odeh, Wioletta Jarmużek, Katarzyna Zachwieja, Agnes Trautmann, Corinne Antignac, Franz Schaefer, on behalf of The PodoNet Consortium
• E-Jahr: 2017
• Jahr: August 10, 2017
• Umfang: 12 S.
• Teil: volume:12
• Teil: year:2017
• Teil: number:8
• Teil: elocationid:e0180926
• Teil: extent:12
• Fussnoten: Gesehen am 11.10.2018
• Titel Quelle: Enthalten in: PLOS ONE
• Ort Quelle: San Francisco, California, US : PLOS, 2006
• Jahr Quelle: 2017
• Band/Heft Quelle: 12(2017), 8, Artikel-ID e0180926
• ISSN Quelle: 1932-6203
• DOI: doi:10.1371/journal.pone.0180926
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1581786921

Abstract

Schimke immuno-osseous dysplasia (SIOD) is a rare multisystem disorder with early mortality and steroid-resistant nephrotic syndrome (SRNS) progressing to end-stage kidney disease. We hypothesized that next-generation gene panel sequencing may unsurface oligosymptomatic cases of SIOD with potentially milder disease courses. We analyzed the renal and extrarenal phenotypic spectrum and genotype-phenotype associations in 34 patients from 28 families, the largest SMARCAL1-associated nephropathy cohort to date. In 11 patients the diagnosis was made unsuspectedly through SRNS gene panel testing. Renal disease first manifested at median age 4.5 yrs, with focal segmental glmerulosclerosis or minimal change nephropathy on biopsy and rapid progression to end-stage kidney disease (ESKD) at median age 8.7 yrs. Whereas patients diagnosed by phenotype more frequently developed severe extrarenal complications (cerebral ischemic events, septicemia) and were more likely to die before age 10 years than patients identified by SRNS-gene panel screening (88 vs. 40%), the subgroups did not differ with respect to age at proteinuria onset and progression to ESKD. Also, 10 of 11 children diagnosed unsuspectedly by Next Generation Sequencing were small at diagnosis and all showed progressive growth failure. Severe phenotypes were usually associated with biallelic truncating mutations and milder phenotypes with biallelic missense mutations. However, no genotype-phenotype correlation was observed for the renal disease course. In conclusion, while short stature is a reliable clue to SIOD in children with SRNS, other systemic features are highly variable. Our findings support routine SMARCAL1 testing also in non-syndromic SRNS.